<![CDATA[Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy]]>

Summary

Dr. Natalie S. Callander discussed the rationale for combining selinexor with carfilzomib, isatuximab, and dexamethasone as a quadruplet regimen for treating relapsed/refractory multiple myeloma. The article represents a clinical discussion at a conference with no new trial data or regulatory decisions announced.